NASH BIOTECHS
An overview on NASH disease
and future treatments
Navigation du site
[Passer]
MAIN
ENGLISH
THE NASH WORLD
NASH INTRODUCTION
WHAT IS KNOWN ABOUT NASH
AROUND THE NASH
NASH DIAGNOSIS
DIAGNOSIS TECHNIQUES
IMAGERY DIAGNOSIS
IMAGERY DIAGNOSIS
BLOOD TEST DIAGNOSIS
BIOTECHS TARGETING NASH
DYNAMIC TIME TO MARKET
LIST OF DRUG CANDIDATES TARGETING NASH(updated weekly)
DYNAMIC TIME TO MARKET
NASH TREATMENT- MARKET FORECAST AND ANALYSIS
POINTS OF VIEW
HOW THE COVID19 IS SHAKING UP THE NASH WORLD
FROM NAFLD TO MAFLD, LAST MOVES !
2019, THE NASH LANDSCAPE
GENFIT POSSIBLES SCENARIOS
WHAT IS THE IMPACT OF THE SELADELPAR MISADVENTURES ON THE PBC AND NASH MARKETS?
WHY BIOTECHS TARGETING NASH COMMUNICATE MORE AND MORE ABOUT DIABETES?
NO ! INTERMEDIATE RESULTS OF SELADELPAR IN NASH ARE NOT A FAILURE!
CYMABAY RESULTS WERE PREDICTABLE AND COHERENTS WITH PPAR's KNOWN ACTION
NASH MARKET! , WE SHOULD STAY REALISTIC
NASH! AND NOW?
OCALIVA INTERMEDIATE RESULTS OF PHASE 3, QUICK ANALYSIS
GILEAD’s POSSIBLES STRATEGIES IN NASH (updated february 2019)
ELAFIBRANOR AND THE NEW PERSPECTIVES OF PPARs IN METABOLIC DISEASES
SOMETHING IS ROTTEN IN THE STATE OF NASH INDUCED FIBROSIS TRIALS
LPCN 1144 RESULTS QUICK ANALYSIS
ELAFIBRANOR AMAZING RESULTS IN PBC
ELAFIBRANOR, A REFERENCE IN NASH, IGNORED BY INVESTORS BUT NOT BY SCIENTISTS.
MGL-3196 RESULTS QUICK ANALYSIS
MADRIGAL MGL-3196 RESULTS IN NASH SEEMS GOOD
NASH! THE INTERIM COHORT RECRUITMENT NEEDED FOR CLINICAL TRIAL PHASE 3 HAS BEEN REACHED FOR THE TWO LEADERS
NASH BIOTECHS ARE UNDER EVALUATED
2018, THE NASH LANDSCAPE
BYZANTINES QUARRELS AN SEX OF ANGELS
NASH TRIAL RECRUITMENT BASICS
LAST LANDSCAPE FOR THE MOST ADVANCED COMPOUNDS IN NASH
OCALIVA ! THE DOUBTS BEFORE PRESCRIPTION !
FDA SAFETY ALERT ON OCALIVA IN PBC WILL UNDOUBTEDLY IMPACT NASH
OCALIVA PATH IS GETTING THINNER BY THE DAY
SEMAGLUTIDE PERSPECTIVES IN NASH
NASH AND NAFLD, WHAT PREVALENCE AND COMORBIDITIES (updated the 22 Aug 2017)
NASH ! THE INTENT TO TREAT POPULATION
INTERCEPT CONTROL TRIAL, WHAT ELSE !
IMMURON - INTERIM ANALYSIS RESULTS - ??? UPDATED
GENFIT’S TEASING REVEALS MOVES
NASH CLINICAL TRIAL RECRUITMENT IS A MESS FOR ALL LABS
INTERCEPT ! CHOICE IS IN THE AIR
FXR AGONISTS, POTENTIAL INDUCED HCC HIGHLIGHTED
NASH - GENFIT- RUMORS AND TRUTHS March 2017
REGENERATE, A BIG CHANGE REVEALING A BIG MESS !
NASH - GENFIT- RUMORS AND TRUTHS
CLINICAL TRIALS IN NASH AND PROBABILITY OF SUCCESS.
GILEAD IN NASH, A SMOKE SCREEN?
NASH ! COMBO’s ARE THE WAY
BIOPSY IN QUESTION ! FALSE NEGATIVES - FALSE POSITIVES
SIMTUZUMAB, AN ENIGM !
ELAFIBRANOR IN PBC , WHY
TARGETING FIBROSIS ALONE IS A NONSENSE
DIAGNOSIS AND LAB STRATEGIES
IN THEIR LAST REPORTS ON NASH , BLOOMBERG COMPARE APPLES AND ORANGES !
COMMENTS ON THE PUBLICATION OF GOLDEN STUDY RESULTS
ALLERGAN / TOBIRA DEAL REVEAL A HUGE GAP BETWEEN FINANCIAL ANALYSTS AND BIG PHARMAS FORECAST ON NASH MARKET
NASH ! SLIDES WAR IS DECLARED!
STATUS REPORT ON NASH (August 2016)
NASH CLINICAL TRIAL PARTICULARISMS
UPDATE ON THE RACE TO NASH MARKET
COMMENTS ON THE 'FITZGERALD CANTOR' POSITION ON ICPT
OCA AND THE LDL CHOLESTEROL !
PHASE III ‘REGENERATE’ RECRUITMENT ! A REASON OF HOURS ?
INTERCEPT PHARMA, PBC AND FDA
GENFIT AND THE CONJUNCTION OF PLANETS(by Gery DIVRY)
ELAFIBRANOR, NEW PERSPECTIVES ...
A NICE ARTICLE ON NASH IN ‘NATURE'
NASH ! TREATMENT’S STRATEGIES AND COMPETITION
NASH INVESTOR CHOICE IN 2016
TAKE THE BIG PICTURE FOR GENFIT
NO DOUBT THAT GENFIT'S DRUG CURES NASH
NEW NASH FINDING FOR GENFIT
THE FUTURE OF INTERCEPT PHARMACEUTICAL IN NASH ? (by Gery DIVRY)
THE NEW DEFINITION OF NASH STRIKE THE NASH PLAYERS (by Gery DIVRY)
A SECOND ANALYSIS ON THE INTERCEPT PHASE 2 ON NASH IN JAPAN (by Gery DIVRY)
WHAT WE LEARN FROM OCA'S FAILURE IN JAPAN
INTERCEPT'S STUDY CURIOSITIES (by Gery DIVRY)
WHY BIOTECH BUBBLE IS ECONOMIC NONSENSE
THE PLUS OF BIOMARKERS
GENFIT'S BIOMARKERS
FGF21, A HORMONE MARKER FOR NASH RESPONDERS
GENFIT PHASE 3 DESIGN
A NASH BIOTECH INVESTOR FILTER (by Gery DIVRY)
FRANCAIS
LE MONDE DE LA NASH
PRESENTATION DE LA NASH
CE QUE L’ON SAIT SUR LA NASH
LE DIAGNOSTIC DE LA NASH
NOUVELLE APPROCHE DU MARCHE
MODELE EVALUATION DU MARCHE DE LA NASH
AUTOUR DE LA NASH
TECHNIQUES DE DIAGNOSTIC
LES BIOTECHS CIBLANT LA NASH
LISTE DES CANDIDATS MEDICAMENTS CIBLANT LA NASH (Mise à jour régulièrement)
ANALYSE DE MARCHE DES TRAITEMENTS POTENTIELS DE LA NASH
NEW DYNAMIC NASH MARKET FORECAST
LE MARCHE DES BIOMARQUEURS
POINTS DE VUE
NEWSLETTER
CONTACT
SITE MAP
Point on the figures to follow the links
NASH INTRODUCTION
BIOTECHS TARGETING NASH
NASH TREATMENT- MARKET FORECAST AND ANALYSIS
POINTS OF VIEW
Tweet
WWW.NASHBIOTECHS.COM - Copyright G DIVRY 2015-2016 -
Contact and TERMS OF USE
[Haut de page]